

CURRICULUM VITAE

INVESTIGATOR NAME Adrián Eduardo Hernández Gauna
NATIONALITY Argentina
PROFESSIONAL REGISTRATION 93599
HOME CENTER Centro de Investigaciones Médicas Mar del Plata
Av. Colón 3083, 1º, 4º, 5º and 7º floor, B7600FYK
Mar del Plata. Bs. As. Argentina
Tel: +54 223 491-7628 / 495-6654 –

EDUCATION: University, date and title obtained

Facultad de Ciencias Medicas de la Universidad Nacional de La Plata. 1999. Title: Medical

GRADUATE: Specialty, dates, names of institutions

-Residence Internal Medicine. 1999-2002. HIGA (Hospital Interzonal General de Agudos) "Dr. Oscar E. Alende". Mar del Plata
- Postgraduated Scholarship of Internal medicine practice. 2002-2003. HIGA "Dr. Oscar E. Alende". Mar del Plata
-Specialist Internal Medicine. 2004. Colegio de Médicos de la Provincia de Buenos Aires
-Specialist Nested in Medical Clinic. 2014. Colegio de Médicos de la Provincia de Buenos Aires
-University teaching carrier. 2009-2011. UNLP (Universidad Nacional de La Plata)
-Monitoring of Clinical Trials and Research course. 2012-2013. Instituto CEMIC
-Good Clinical Practice (GCP) certificate. Johnson & Johnson Family of Companies. November 30, 2014
-Training Certificated Of Good Clinical Practice (GCP). FEFYM. November 2016
-Training in Ethics of the research. Conducted by Dr. Ignacio Maglio. Aug 2017
-Sep 2018- Curso de Etica y Buenas Practicas Clínicas de Investigación. Ministerio de Salud de la Nación, duration 80 hs
-July 2019 Good Clinical Research Practice. Brookwood
-Aug 2022- Good Clinical Research Practices NIDA Clinical Trials Network

TEACHING

1996-2003 Teaching in the Department of Internal Medicine, Facultad de Ciencias Medicas de la UNLP
2008-2013 Teaching in Residence Internal Medicine. Clinica Pueyrredón. Mar del Plata

PROFESSIONAL EXPERIENCE

Current work:

-Internal Medicine Private practice from 2002 to date
Since 2014-Physician of the staff Centro de Investigaciones Médicas Mar del Plata

Previous work:

-Medical PAMI header from 2007 to 2022
-Medical Emergency in Clínica del Niño y la Madre, Clínica Colón and Clínica Pueyrredón of Mar del Plata from 2002-2009
-Medical Internist in Clínica del Niño y la Madre y Clínica Colón from 2002-2005

COURSES

1999 -Semiologia Neurology (Dr. Arzeno) HIGA "Dr. Oscar E. Alende". Mar del Plata
2002 -Primary Attention in Internal Medicine. SAMIG (Sociedad Argentina de Medicina Interna General) Duration 1 year
2004 -Update and Recertification in Internal Medicine. 125 hs
2006 -Update graduate in Medicine (Clínica Pueyrredón) 1 year
2007 -Postgraduate Course for Primary care Physicians. UNLP. 210 hs
2008 -Of the clinic trials. Instituto de Investigaciones Clínicas, FECICLA and Universidad FASTA
2009 -Advances in the Diagnosis and Treatment. Escuela Superior de Educación Médica del IX Distrito del Colegio de Médicos de la provincia de Bs As. 205 hs
-Role University Teaching. UNLP. 120 hs
2010 -The teaching of learning in medical education. UNLP. 120 hs
2011 -Evaluation in medical education. "UNLP. 120 hs
2012/13 -Management and Monitoring of Clinical Trials Research. Instituto Universitario CEMIC. 120 hs
2013 -Update on Hypertension 2013. FAC (Federación Argentina de Cardiología) 50 hs

MEETINGS, CONFERENCES AND SYMPOSIA

- 1999 -X Congress SAMIG
- Symposium Upgrade Tuberculosis and AIDS. (Dr. González Montaner, Dr. Ferro) HIGA "Dr. Oscar E. Alende". Mar del Plata
-First Regional Conference of Professional Nursing Homes
- 2000 -XI Congress of the SAMIG
- 2001 -First Conference of the Association of primary care physicians Mar del Plata
-XI Argentine Congress of Hepatology
-Program Continuing education of the Argentina Association for the Study of Liver Diseases
- 2002 -XXI National Congress of Cardiology. FAC
-9 ° International Congress of Internal Medicine, Hospital de Clínicas
- 2004 -IV Argentine Congress SADI (Sociedad Argentina De Infectología)
- 2005 -V Argentine Congress SADI
- 2008 -First Conference on Drug Clinical Research. Instituto de Investigaciones Clínicas, FECILCLA and Universidad FASTA
- 2010 -13° International Congress of Internal Medicine, Hospital de Clínicas. Autonomous City of Buenos Aires. Buenos Aires. Argentina
-43 ° Argentine Congress of Rheumatology
- 2011 -Congress International Medical Clinic and Internal Medicine
- 2013 -2 ° Congress of Internal Medicine of the Atlantic Coast
- 2014 -X International Symposium "Functional gastrointestinal disorders". Cidemo
-Days Gastroenterological Atlantic. Federación Argentina de Gastroenterología. Sociedad Marplatense de Gastroenterología y Coloproctología

PAPERS PRESENTED

- 2000 -Importing neurocysticercosis. XI Congress of the SAMIG
-ACV ... And its risk factors? XI Congress of the SAMIG
- 2003 -Comparative Study of Breathalyzer vs. Observed -ESCAVYO- and 91. Prize for the best work in the area of Epidemiology. Sociedad Argentina de Medicina
- 2004 -Functional Evaluation of the elderly patient in office. Posted in Update and Recertification Course in Internal Medicine
- 2011 -Spontaneous Neumomediastino (Hamman syndrome). I Congress of Internal Medicine of the Atlantic Coast. Mar del Plata
-Fluctuating focal neurological deficits in HIV patient. I Congress of Internal Medicine of the Atlantic Coast. Mar del Plata
- 2012 -Atypical Presentation of acute abdominal pain in diabetic patients. XX National Congress of Medicine 2012. SAM (Sociedad Argentina de Medicina)

PROFESSIONAL EXPERIENCE IN CLINICAL RESEARCH

- VESTRI** Phase III Asthma in children Since Dec-2014 -2016 Sub investigator
- SUMMIT** Phase III COPD Since Jan-2015-2016. Sub investigator
- EXSCEL** Phase III Diabetes 2 and CV valuation Since Jan-2015-2017. Sub investigator
- CQVA** Phase III. Epoc. Since 2014-2016. Sub Investigator
- EUCLID** Phase IIIb Peripheral vascular disease. Since 2014-2016. Sub Investigator
- CANTOS** Phase III Acute myocardial infarction. Since 2014-2017 Sub Investigator
- ODYSSEY** Phase IIIb. Acute coronary syndrome. Since 2014-2017. Sub Investigator
- DECLARE** Phase IIIb. Diabetes type II and cardiovascular risk. Since 2014-2018. Sub Investigator
- B12610007** Phase III. Diabetic nephropathy. Since 2014-2015. Sub Investigator
- NN-95353626**. Phase IIIa. Diabetes type II and Metformina failure. Since 2014-2016. Sub Investigator
- DIA4003**. Phase III. Diabetes II and cardiovascular risk.2014-2017 Sub Investigator
- JADY**. Phase III. Rheumatoid arthritis. Since 2015. Sub Investigator
- ABBVIE**. Phase III Kidney failure and diabetes. Since 2015-2018. Sub Investigator
- CTT** Phase III COPD Since Apr-2015-2017. Sub investigator
- MK-018**. Phase III. Diabetes type II and cardiovascular risk. Since 2014-2016. Sub Investigator
- AMGEN 0142**. Phase III. Osteoporosis.2014-2017 Sub investigator
- MK 8835-001**. Phase III .Diabetes Since 2015 to 2017. Sub Investigator
- MK 8835-005**. Phase III. Diabetes. Since 2015 to 2017. Sub Investigator
- THEMIS**. Fase III.Diabetes with cardiovascular risk. Since 2015-2019 Sub Investigator
- GEMINI**. Phase III. Cardiovascular event 2016-2017. Sub investigator
- TERRANOVA**. Phase III. COPD. Since 2015-2018 Sub Investigator.
- MARINER** Phase III. Risk of venous thromboembolism at discharge. Since 2015-2017. Sub investigator
- CV185316 AUGUSTUS**. Phase IV. Atrial fibrillation and acute coronary syndrome. Since 2016-2019 Sub investigator

OLYMPUS. Phase III. Chronic Renal Failure with Anemia. Since 2016-2018 Sub investigator
CREDESCENCE. Phase III. Chronic Renal Failure with diabetes Since 2016 -2018 Sub investigator
VOYAGER. Phase III. Risk of thrombotic vascular events. Since 2016 Sub investigator
GA 28949. Phase III.. Moderate to severe ulcerative colitis Since 2017. Sub investigator
GA 28951. Phase II/III Extensión. Moderate to severe ulcerative colitis. Since 2017 Sub investigator
PT010005 Phase III COPD. Since 2017. Sub Investigator.
PT009003 SOPHOS. Phase III COPD. Since 2017-2018. Sub investigator
MK0431-848. Phase III DBT 2. Since 2017-2018 Sub investigator
MK0431/845 Phase III. DBT 2. Since 2017-2018 Sub investigator
MK8835-004-01/B1521021. Phase III Diabetes 2 with established vascular disease Since 2017. Sub Investigator.
ASCEND-200808 Phase III. Anemia associated with chronic kidney disease. Since 2017. Sub investigator
AKB-6548-CI-0015. Phase III. Anemia associated with chronic kidney disease. Since 2017. Sub investigator
AKB-6548-CI-0014. Phase III. Anemia associated with chronic kidney disease. Since 2017. Sub investigator
DAPA CKD- D169AC00001. Phase III. Chronic renal disease. Since 2017. Sub investigator
DAPA HF D1699C00001. Phase III. Chronic heart failure with reduced ejection fraction. 2017 Sub Investigator
MNK4049. Phase III. Focal and segmental sclerosis. Since 2017 Sub investigator
MLN0002SC-3030 Phase IIIb ulcerative colitis Since 2017-2018 Sub investigator
MLN0002SC-3031 Phase III. ulcerative colitis Since 2017-2018 Sub investigator
PROMINENT. Phase III. Cardiovascular disease, triglyceride reduction in diabetic patients. Since 2017. Sub investigator
ETC1002-043CLEAR OUTCOMES. Phase III. Intolerance to statins with cardiovascular risk. Since 2017. Sub investigator
GA29350 Phase II Rheumatoid arthritis.. Since 2017. Sub Investigator
GA30067 extention Phase II Rheumatoid arthritis.. Since 2018 Sub Investigator.
BI1245.110. Phase III.. Chronic heart failure with preserved ejection fraction .Since 2018. Sub investigator
BI 1245.121. Phase III Chronic heart failure with reduced ejection fraction. Since 2018. Sub investigator
EFC14875. SCORED Phase III Cardiovascular and renal events in patients with DBT II, cardiovascular risk factors and moderate failure. Since 2018. Principal Investigator
EFC14837 Phase III Diabetes with moderate renal disease. Since 2018 Sub Investigator
EFC15116 Phase III Diabetes with severe kidney disease. Since 2018 Sub Investigator
CREDO 2 / CLO4041023. Phase III Rheumatoid arthritis. Since 2018. Sub Investigator
CREDO 3 / CLO4041025. Phase III Rheumatoid arthritis. Since 2018. Sub Investigator
205270 Phase III Anemia associated with chronic kidney disease. Since 2018. Sub Investigator
HZA107116. Phase III Astma in children 5 to 17 years old. Since 2018 Sub investigator
204837 Phase III. Dialysis patients with anemia related to chronic kidney disease. Since 2018. Sub Investigator
CREDO 4/CLO041024. Phase III Rheumatoid arthritis Since 2019 Sub investigator
RLM-MD-02 Phase III diabetic gastroparesis. Since 2019 Sub investigator
RLM-MD-03 Extensión Phase III diabetic gastroparesis. Since 2019 Sub investigator
RLM-MD-04 Phase III diabetic gastroparesis. Since 2019 Sub investigator
DELIVER Phase III Chronic heart failure with preserved ejection fraction . Since 2019 Sub Investigator
BOREAS Fase III. EPOC. Desde 2020. Sub Investigador
CONTRAST 1 201790- Phase III Rheumatoid arthritis. Since 2020 Sub Investigador
CONTRAST 2 202018- Phase III Rheumatoid arthritis. Since 2020 Sub Investigador
CONTRAST X- (extension) Phase III Rheumatoid Arthritis. Since 2020 Sub Investigator
TRICIDA, Fase IIIb Acidosis Metabólica. Desde 2019 Sub Principal
PLATFORM PACRD2001- Phase II Crohn's Disease Sub Investigator Since 2020
QUASAR CNTO1959UCO3001 Phase IIb/III Ulcerative colitis. Sub Investigator Since 2020
NODE 303. Phase III. Paroxysmal Supraventricular tachycardia. Sub Investigator. Since 2020
MIT-Do001-C301(Estetra) Phase III. Post menopausal woman with vasomotor symptoms. Sub Investigator. Since 2020
READY 1 (Cusa) Phase III. Use of Cusa-081 for dysfunction of central venous access devices (DAVC) Sub Investigador. Since 2020
209564 Phase III Rheumatoid arthritis Sub Investigator. Since 2020
MATINEE Phase IIIA. COPD with eosinophilic levels. Since 2021. Sub Investigator
AMETHYST Phase II. Heart failure with preserved EF. Since 2021. Sub Investigator Investigator
AMEERA-5 Phase III. Breast cancer Since 2021. Sub Investigator
213400 Phase III Non-small cell lung cancer. Since 2021 Sub Investigator
ARENA APD334-202 Phase III. Crohn's disease. Since 2021 Sub Investigator

MEDI3506 Phase IIb. Diabetic nephropathy. Since 2021 Sub Investigator
1366,0002 Phase III Non-diabetic kidney disease. Since 2021 Sub Investigator
1366,0005 Phase III Diabetic chronic kidney disease. Since 2021 Sub Investigator
CC-93538-EE-01 Phase III Eosinophilic esophagitis. Since 2021 Sub Investigator
ANJ900D3501 Phase III Diabetes with variable renal function. Since 2021. Sub Investigator
D7551C00001 Phase IIb. Chronic proteinuric kidney disease. Since 2021 Sub Investigator
DIALIZE Phase III Arrhythmia in patients on chronic hemodialysis due to recurrent hyperkalemia. Since 2021 Sub Investigator
INS1007-301 ASPEN Stage III Bronchiectasis. Since 2021 Sub Investigator
GKPTN Platform Study. Since 2021 Sub Investigator
TACKLE Phase III Treatment of Covid in non-hospitalized adult patients. Since 2021 Sub Investigator
KANGTAI Phase III Covid-19 Vaccine Since 2021 Sub-Investigator
BANNER Phase IIIA HIV Since 2021 Sub Investigator
RPC01-3201 Moderate to severe Crohn's disease From 2022 Sub Investigator
ZEUS Phase III Cardiovascular disease, chronic renal failure. Since 2022 Sub Investigator
ALIGN Phase III IgA nephropathy and progressive loss of renal function. Sub Investigator
STABILIZE Phase III Chronic kidney disease and hyperkalaemia From 2022. Sub Investigator
D4325C00001 ZENIT Phase IIB CKD with glomerular filtration rate between 20 and 60 ml/min/1.73 m2 Sub Investigator
PILASTER Phase III Epop and chronic bronchitis. Since 2021. Sub Investigator
GB4311 Phase IIb COPD. Since 2022 Sub-Investigator.
GO42784 LIDERA Phase III Breast cancer. Since 2022 Sub-Investigator
23OLE304 TOPAZ Phase III Lupus. Since 2022 Sub-Investigator
WILLOW Phase II Lupus erythematosus. Since 2022. Sub-Investigator
SURMOUNT I8F-MC-GPIJ Phase III Obesity. Since 2023. Sub-Investigator
RPC01-3204 Moderate to severe Crohn's disease. Since 2022 Sub-Investigator
RPC01-3203 Moderate to severe Crohn's disease. Since 2022 Sub-Investigator
CC-93538-EE-02 (Extension) Phase III Eosinophilic esophagitis. Since 2022 Sub-Investigator
BI 1378-0005 Chronic kidney disease. Since 2022. Principal Investigator
JASMINE 80202135SLE2001 Systemic Lupus Erythematosus (SLE) Since 2023. Sub Investigator
MS200569_0048 WILLOW LTE Phase II Lupus erythematosus Since 2023. Sub-investigator
J2A-MC-GZGU Phase III Adults with type 2 diabetes and inadequate glycemic control with Metformin. Since 2023 Principal investigator
23OLE301 (AMETHYST) Phase II Cutaneous lupus erythematosus. Since 2023 Sub Investigator
EX6018-4915 HERMES Phase III Patients with heart failure and inflammation. Since 2023 Sub Investigator
70033093AFL3002 LIBREXIA AFL Phase III Patients with Atrial Fibrillation Since 2023 Sub Investigator
70033093ACS3003 LIBREXIA ACS Phase III Acute coronary syndrome. Since 2023 Subinvestigator
CR845-310302 KICK 2 Phase III ITCH OF MODERATE INTENSITY A SEVERE IN SUBJECTS WITH CHRONIC KIDNEY DISEASE. Since 2023 Sub Investigator
ADVANCED
ACTIV-2b SCORPIO-HR Phase III Non-hospitalized patients with COVID-19 Since 2023 Sub-investigator
AT-03A-017 Phase III High-risk outpatients with COVID-19. Since 2023 Subinvestigator
209978 MARS-17 Phase II Osteoarthritis of the knee. Since 2023 Subinvestigator
AMG592 20170104 Phase II Moderate to severe ulcerative colitis. Since 2022 Subinvestigator
AMG592 20210210 EXT Phase II Moderate to severe ulcerative colitis. Since 2022 Subinvestigator
CNT01959UCA3004 ASTRO Phase III Moderately to severely active ulcerative colitis. Since 2023 Subinvestigator
K-001-201 Phase II NASH. Since 2023 Subinvestigator
BUS-P3-01 CALM Bellus Phase III Refractory chronic cough. Since 2023 Sub Investigator
EDP 938-104 ENANTA Phase IIb Acute syncytial respiratory virus. Since 2023 Subinvestigator
GB43374 OLE COPD Since 2023 Sub-researcher
CLI-06001AA1-04 PILASTER Phase III COPD Since 2023 Sub Investigator
CLI-06001AA1-05 PILAR Phase III COPD Since 2023 Sub Investigator
CLI-05993AA-06 TRITON Phase III COPD Since 2023 Sub Investigator
1368-0098 Phase IIb/III. Hidradenitis suppurativa. Since 2023 Sub Investigator
INCB 18424-319 Phase III Prurigo nodularis. Since 2023 Sub Investigator
77242113PSO3001 Phase III Moderate to severe plaque psoriasis. Since 2023 Sub Investigator
1366-0031 Phase II Cutaneous sclerosis. Since 2023 Sub Investigator
D6970C00002 BaxHTN Phase III Participants with Hypertension Uncontrolled on Two or More Medications including Participants with Resistant Hypertension Since 2024 Sub Investigator
MK 7240-001 CU Phase III participants with moderately to severely active ulcerative colitis Since 2024 SubInvestigator

219700 VOLITION Phase IIIb HIV-1 in antiretroviral therapy-naïve adults Sub Investigator Since 2024
23OLE306 (EMERALD) Phase III Systemic lupus erythematosus. Since 2024 Sub Investigator
D4325C00007 Chronic kidney disease and proteinuria. Since 2024 Sub Investigator
D7830C00004 FORTUNA Phase IIb. Non-alcoholic non-cirrhotic steatohepatitis with fibrosis (NASH)
Since 2024 Sub Investigator
D4325C00010 ZENITH Phase III Chronic kidney disease and high proteinuria. Since 2024 Sub
Investigator
MRXC-302 Phase III Moderate disease or severe diabetic foot infections. Since 2024 Sub Investigator
ACT17746 LIBERTY Phase II Ulcerative colitis with eosinophilic profile. Since 2024 Sub Investigator
78934804UCO2001 (DUET-UC) Phase IIb Moderately to severely active ulcerative colitis. Since 2024
Sub Investigator

DATE: 15 JAN 2024

SIGNATURE:

ADRIAN HERNANDEZ GAUNA
SPECIALISTA JERARQUIZADO
EN CLÍNICA MEDICA
M.P. 93, 599